Celldex (CLDX) Announces Glembatumumab Vedotin Phase 2 Met Primary Objective in c/r Metastatic Melanoma
Tweet Send to a Friend
Celldex Therapeutics, Inc. (Nasdaq: CLDX) presented positive results from the Company’s Phase 2 study of glembatumumab vedotin in patients with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
